153 related articles for article (PubMed ID: 30964768)
1. Immune-related pancreatitis associated with checkpoint blockade in melanoma.
Kohlmann J; Wagenknecht D; Simon JC; Ziemer M
Melanoma Res; 2019 Oct; 29(5):549-552. PubMed ID: 30964768
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
3. Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
Su Q; Zhang XC; Zhang CG; Hou YL; Yao YX; Cao BW
J Immunol Res; 2018; 2018():1027323. PubMed ID: 29971244
[TBL] [Abstract][Full Text] [Related]
4. Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Grätz V; Langan EA; Neumann A; Zillikens D; Terheyden P
Melanoma Res; 2019 Oct; 29(5):516-521. PubMed ID: 30870272
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
[No Abstract] [Full Text] [Related]
7. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
12. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
13. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Bermudez MV; Papa S
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
[TBL] [Abstract][Full Text] [Related]
14. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
15. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
Trinh B; Sanchez GO; Herzig P; Läubli H
J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
[TBL] [Abstract][Full Text] [Related]
17. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
18. Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.
Michot JM; Ragou P; Carbonnel F; Champiat S; Voisin AL; Mateus C; Lambotte O; Annereau M
J Immunother; 2018; 41(2):84-85. PubMed ID: 29252914
[TBL] [Abstract][Full Text] [Related]
19. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis.
George J; Bajaj D; Sankaramangalam K; Yoo JW; Joshi NS; Gettinger S; Price C; Farrell JJ
Pancreatology; 2019 Jun; 19(4):587-594. PubMed ID: 31076344
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
